BioXcel Therapeutics (Nasdaq BTAI) - Listen to the 8/31 court hearing re bankruptcy/asset sale, #pharma #Teva #IGALMI #agitation #BXCL501 #schizophrenia #bipolardisorder #AI #neuroscience #onkosxcel #dexmedetomidine
American court hearing recordings and interviews by Center of Main Interests
Episode notes
Per BioXcel's press release:
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
Aug 28, 2026
BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders
Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process
BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations
NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial i ...
Keywords
bankruptcychapter 11TevapharmaIGALMI